Effectiveness and Safety of Carbamazepine versus Gabapentin in the Pharmacological Management of Trigeminal Neuralgia: Carbamazepine vs Gabapentin in Trigeminal Neuralgia

Maria Jabbar; Uzair Bin Akhtar; Komal Akram; Mustafa Ayub Khawaja; Muhammad Khalil

doi:10.54393/pjhs.v6i12.3453

Authors

Maria Jabbar Department of Oral and Maxillofacial Surgery, Sharif Medical and Dental College, Lahore, Pakistan
Uzair Bin Akhtar Department of Oral and Maxillofacial Surgery, Sharif Medical and Dental College, Lahore, Pakistan
Komal Akram Department of Oral and Maxillofacial Surgery, Sharif Medical and Dental College, Lahore, Pakistan
Mustafa Ayub Khawaja Department of Oral and Maxillofacial Surgery, Sharif Medical and Dental College, Lahore, Pakistan
Muhammad Khalil Department of Oral and Maxillofacial Surgery, Sharif Medical and Dental College, Lahore, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v6i12.3453

Keywords:

Carbamazepine, Gabapentin, Safety, VAS Score

Abstract

Carbamazepine is considered the first-line pharmacological therapy for trigeminal neuralgia (TN). Gabapentin, another antiepileptic drug, is increasingly used, but its role as a substitute for carbamazepine remains uncertain. Objectives: To compare the effectiveness and safety of gabapentin and carbamazepine in the management of trigeminal neuralgia. Methods: This prospective comparative study included 80 patients presenting to the Department of Oral and Maxillofacial Surgery at Sharif Medical and Dental Hospital from February 2023 to January 2024. Patients were divided into two groups of 40 each: Group A received gabapentin 300 mg twice daily, and Group B received carbamazepine 200 mg twice daily. Pain intensity was assessed using the Visual Analogue Scale (VAS), and frequency of attacks was recorded on the 3rd, 7th, and 15th days of follow-up. Side effects were also documented. Mann-Whitney U and Chi-square tests were used for statistical analysis, with p≤0.05 considered significant. Results: Group A exhibited lower median VAS scores compared to Group B at all follow-up intervals, with statistically significant differences on the 2nd and 3rd follow-ups. Although gabapentin demonstrated fewer adverse effects, carbamazepine showed the highest percentage of good therapeutic response based on reduced frequency of attacks. Conclusions: Both drugs are effective in managing trigeminal neuralgia. Carbamazepine provides superior pain relief and reduction in attack frequency, whereas gabapentin is associated with fewer side effects.

References

Munoz‐Vendrell A, Valín‐Villanueva P, Tena‐Cucala R, Campoy S, Martinez‐Yélamos S, Huerta‐Villanueva M. Second-Line Pharmacological Treatment Strategies for Trigeminal Neuralgia: A Retrospective Comparison of Lacosamide, Gabapentin and Baclofen. Headache: The Journal of Head and Face Pain. 2025 May. doi: 10.1111/head.14952.

Basu I, Perry M. Initial assessment of the “Head and Neck” patient. InDiseases and Injuries to the Head, Face and Neck: A Guide to Diagnosis and Management 2021 Feb 17 (pp. 57-134). Cham: Springer International Publishing.

Cao X, Shen Z, Wang X, Zhao J, Liu W, Jiang G. A Meta-Analysis of Randomized Controlled Trials Comparing the Efficacy and Safety of Pregabalin and Gabapentin in the Treatment of Postherpetic Neuralgia. Pain and Therapy. 2023 Feb; 12(1): 1–8. doi: 10.1007/s40122-022-00451-4.

Flickinger JC Jr, Kim H, Kano H, Greenberger JS, Arai Y, Niranjan A, et al. Do Carbamazepine, Gabapentin, or Other Anticonvulsants Exert Sufficient Radioprotective Effects to Alter Responses from Trigeminal Neuralgia Radiosurgery? International Journal of Radiation Oncology Biology Physics. 2012 Jul; 83(4): e501–e506. doi: 10.1016/j.ijrobp.2012.01.016.

Fricke-Galindo I, LLerena A, Jung-Cook H, López-López M. Carbamazepine Adverse Drug Reactions. Expert Review of Clinical Pharmacology. 2018 Jul; 11(7): 705–718. doi: 10.1080/17512433.2018.1486707.

Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for Acute and Chronic Pain. Cochrane Database of Systematic Reviews. 2005; CD005452. doi: 10.1002/14651858.CD005452.

AlHabil Y, Al-Sayed K, Salameh A. Trigeminal Neuralgia Improvement Following Transcutaneous Electrical Nerve Stimulation (TENS): A Systematic Review and Meta-Analysis. BMC Neurology. 2025 Jan; 25(1): 13. doi: 10.1186/s12883-024-04014-2.

Khadilkar SV and Patil VA. Medical Management of Trigeminal Neuralgia. Neurology India. 2021 Mar; 69(Suppl 1): S199–S205. doi: 10.4103/0028-3886.315996.

LeDoux JE et Pine DS. Using Neuroscience to Help Understand Fear and Anxiety: A Two-System Framework. American Journal of Psychiatry. 2016 Nov; 173(11): 1083–1093. doi: 10.1176/appi.ajp.2016.16030353.

Lee JY, Lee GH, Yi SH, Sim WS, Kim BW, Park HJ. Non-Surgical Treatments for Trigeminal Neuralgia from the Perspective of a Pain Physician: A Narrative Review. Biomedicines. 2023 Aug; 11(8): 2315. doi: 10.3390/biomedicines11082315.

Agarwal R and Kumari S. Comparison of Carbamazepine and Gabapentin in Management of Trigeminal Neuralgia: A Clinical Study. Journal of Advanced Medical and Dental Sciences Research. 2020 Nov; 8(11): 38–41.

Agarwal A, Kaur R, Ashfaque F, Hadi Z, Anis MW, Ali A, et al. Precision Medicine Approaches in Epilepsy: A Systematic Review of Genetic Markers and Personalized Treatment Strategies. Precision Medical Sciences. 2024 Jun; 13(2): 72–83. doi: 10.1002/prm2.12139.

World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Journal of the American Medical Association. 2013 Nov; 310(20): 2191–2194. doi: 10.1001/jama.2013.281053.

Copes LE, Lucas LM, Thostenson JO, Hoekstra HE, Boyer DM. A Collection of Non-Human Primate Computed Tomography Scans Housed in MorphoSource: A Repository for 3D Data. Scientific Data. 2016 Feb; 3(1): 1–8. doi: 10.1038/sdata.2016.1.

Ma Y, Du H, Zheng S, Zhou Z, Zhang H, Ma Y, et al. High-Entropy Approach vs. Traditional Doping Strategy for Layered Oxide Cathodes in Alkali-Metal-Ion Batteries: A Comparative Study. Energy Storage Materials. 2025 May. doi: 10.1016/j.ensm.2025.104295.

Guo M, Shen W, Zhou M, Song Y, Liu J, Xiong W, et al. Safety and Efficacy of Carbamazepine in the Treatment of Trigeminal Neuralgia: A Meta-Analysis in Biomedicine. Mathematical Biosciences and Engineering. 2024 Mar; 21(4): 5335–5359. doi: 10.3934/mbe.2024235.

De Stefano G, Di Pietro G, Truini A, Cruccu G, Di Stefano G. Considerations when Using Gabapentinoids to Treat Trigeminal Neuralgia: A Review. Neuropsychiatric Disease and Treatment. 2023 Dec; 2007–2012. doi: 10.2147/NDT.S407543.

Pergolizzi JV Jr, Gharibo C, Magnusson P, Breve F, LeQuang JA, Varrassi G. Pharmacotherapeutic Management of Trigeminal Neuropathic Pain: An Update. Expert Opinion on Pharmacotherapy. 2022 Jul; 23(10): 1155–1164. doi: 10.1080/14656566.2022.2087507.

Iqbal S, Rashid W, ul Ain Q, Atiq T, Noor R, Irfan F. Efficacy of Carbamazepine and Oxcarbazepine for Treating Trigeminal Neuralgia. BMC Journal of Medical Sciences. 2022; 3(2): 55–59. doi: 10.70905/bmcj.03.02.062.

Zhao X, Ge S. The Efficacy and Safety of Gabapentin vs. Carbamazepine in Patients with Primary Trigeminal Neuralgia: A Systematic Review and Meta-Analysis. Frontiers in Neurology. 2023 May; 14: 1045640. doi: 10.3389/fneur.2023.1045640.